BillionToOneBLLN +2.04%13 PS Ratio is 16.32 as of Jul. 01, 2026, which is 26% above its 10-year median of 12.96. GuruFocus rates BLLN with a GF Score™ of 13/100. The stock has 5 warning signs investors should review. Among 200 Medical Diagnostics & Research companies, BillionToOne ranks worse than 89.5% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, BillionToOne's share price is $122.33.
BillionToOne's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $7.50. Hence, BillionToOne's PS Ratio for today is 16.32.
The historical rank and industry rank for BillionToOne's PS Ratio or its related term are showing as below:
BLLN'
s PS Ratio Range Over the Past 10 Years
Min: 10.21 Med: 12.96 Max: 22.38
Current: 16.3
During the past 3 years, BillionToOne's highest PS Ratio was 22.38. The lowest was 10.21. And the median was 12.96.
BLLN's PS Ratio is ranked worse than 89.5% of 200
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.815
vs BLLN: 16.30
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
BillionToOne PS Ratio Related Terms
BillionToOne PS Ratio Historical Data
* Premium members only.
The historical data trend for BillionToOne's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, BillionToOne's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BillionToOne PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, BillionToOne's PS Ratio distribution charts can be found below:
* The bar in red indicates where BillionToOne's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
BillionToOne's PS Ratio for today is calculated as
BillionToOne's Share Price of today is $122.33. BillionToOne's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.50.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
BillionToOne (BLLN) has a PS Ratio of 16.32 as of Jul. 01, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on BillionToOne and its competitors. This is 26% above median its historical median of 12.96. Over the past decade, BillionToOne's PS Ratio has ranged from 10.21 to 22.38. According to the industry distribution chart, BillionToOne ranks #179 out of 200 companies in the Medical Diagnostics & Research industry, placing it in the top 89.5%.
Is BillionToOne's PS Ratio too high?
BillionToOne's current PS Ratio of 16.32 is 26% above median its 10-year median of 12.96. Over the past 10 years, this metric has ranged from a low of 10.21 to a high of 22.38. The Medical Diagnostics & Research industry median PS Ratio is 2.82. BillionToOne's value of 16.32 is 479.8% above this industry median. Based on the distribution chart, BillionToOne ranks #179 out of 200 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, BillionToOne has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does BillionToOne's PS Ratio compare to SHC and VCYT?
According to the Medical Diagnostics & Research industry distribution chart, BillionToOne ranks #179 out of 200 companies for PS Ratio. This places BillionToOne in the lower half of its industry. The industry median PS Ratio is 2.82. BillionToOne's value of 16.32 is 479.8% above this benchmark. Historically, BillionToOne's own PS Ratio has ranged from 10.21 to 22.38 over the past decade. While the company's 10-year median is 12.96 vs. the industry median of 2.82, BillionToOne has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Diagnostics & Research company?
The median PS Ratio among Medical Diagnostics & Research companies is 2.82, based on 200 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BillionToOne's current PS Ratio of 16.32 is 479.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on BillionToOne and its competitors. For the Medical Diagnostics & Research industry, the median PS Ratio is 2.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BillionToOne's current PS Ratio is 16.32, which is 26% above median its own 10-year median of 12.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BillionToOne stock overvalued right now?
BillionToOne (BLLN) has a current PS Ratio of 16.32. The current PS Ratio is 16.32, which is 26% above median its 10-year median of 12.96 and 479.8% above the Medical Diagnostics & Research industry median of 2.82. BillionToOne's overall GF Score™ is 13/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For BillionToOne (BLLN), the current PS Ratio is 16.32 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
13GF Score
Get the complete analysis for BLLN
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLLN has been successfully added to your 